Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole in neoadjuvant breast cancer
NCT01972984Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2012
- Primary completion
- Aug 2014
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of anastrozole in breast cancer, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Percentage of patients who fit the eligibility criteria that consent to the study; withdraw after consent from the study at 18 months. Started Oct 2012; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01972984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972984.